Burooyinka neuroendocrine ee ganaca (NETs) badanaa si tartiib tartiib ah ayey u koraan, shaybaarkuna wuxuu la socdaa burada calaamadaha koritaanka iyada oo loo marayo tijaabooyin sawireed. Bukaanada qaba NET-ka oo ku faafaya xameetida waxay badanaa leeyihiin calaamado ay ka mid yihiin shuban ama dhibaatooyin hormoon. Waxaa loo isticmaali karaa daawooyinka sida octreotide, lanreotide, diazoxide, iyo proton pump inhibitors, kuwaas oo joojin kara koritaanka burada.
When the patient’s symptoms cannot be controlled or the scan shows signs of buro growth, further treatment is required, and chemotherapy or targeted drugs (such as sunitinib or everolimus) can be used. For people with poorly differentiated tumors (neuroendocrine carcinoma), chemotherapy is the first choice. For patients who have spread to the liver, choose surgery or ablation technology for treatment according to their own conditions. For adults with somatostatin (a hormone) receptor-positive pancreatic neuroendocrine tumor, the radiopharmaceutical Lutathera (l Lu177 dotatate) is a treatment option.
If all feasible treatments no longer work, then consider participating in clinical trials to test new therapies. Participation in clinical trials is likely to benefit some patients.
